Tracking skin disease severity in adults with dermatomyositis using a scoring tool
Follows adults with dermatomyositis, using a skin severity score to track changes.
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- Jun 2008
- Expected to end
- 2 Jan 2030
- Type of study
- Observational
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with dermatomyositis that affects the skin. It collects data on how the skin disease changes over time and how it affects daily life.
- Age
- Above 18 years old.
- Sex
- Males and females can join.
- Disease stage
- Dermatomyositis with skin involvement (cutaneous dermatomyositis).
Main reasons for not taking part
- People without dermatomyositis of the skin
- Employees of Penn (University of Pennsylvania)
- Students of Penn (University of Pennsylvania)
- People with problems in thinking or memory
- People who cannot give informed consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Gender/Age: Males or females above 18 years old
- Diagnosis: Cutaneous Dermatomyositis
- Subjects able to give informed consent
Who cannot take part
- Subjects without cutaneous DM
- Penn employees
- Penn students
- Cognitively impaired persons
Where in United States
- Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Victoria P Werth, MDTaking people
About the trial
What the trial wants to find out
The Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), established in 2008, is a one-site database study conducted at the University of Pennsylvania. The database has yielded valuable information and clinical insights into the pathophysiology, disease processes, including psychological responses, treatments and quality of life associated with dermatomyositis. The CDASI database incorporates the Cutaneous Dermatomyositis Disease Area and Severity Index), a validated outcome measure of disease responsiveness in patients, and other assessment tools, surveys and patient information to help validate the clinical course and quality of life of patients with dermatomyositis.
Read full original descriptionShow less
The CDASI database has led to publication of comparison studies of CDASI and other clinical instruments and the effect of dermatomyositis on Quality of Life (QoL).
The CDASI database is an ongoing resource that enables clinicians to evaluate the evolving clinical changes, treatment modalities and patient response to a challenging disease. Data will be analysed over a 5 years.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
- Plain-language title
- Tracking skin disease severity in adults with dermatomyositis using a scoring toolGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 30 March 2026